INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
What's Going On With Replimune Stock On Tuesday?
FDA Commissioner Makary defends agency's decision on Replimune's drug
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
FDA Rejection Sparks Questions On Replimune Drug Approval Path
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Replimune melanoma therapy rejected by FDA, shares plunge
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'
Stock Market Today (LIVE): Futures Rebound as Investors Shift Focus to Bank Earnings Despite U.S. Navy Blockade and Rising Crude
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
US FDA declines to approve Replimune's drug for advanced skin cancer
Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares of Stock
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Analysts
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
Replimune to Present at Two Upcoming Investor Conferences
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
SG Americas Securities LLC Increases Stake in Replimune Group, Inc. $REPL
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Squarepoint Ops LLC Grows Stock Position in Replimune Group, Inc. $REPL
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Moderate Buy” by Brokerages
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Why Replimune Stock Was Soaring Today
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPL
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL